4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

• Status: Withdrawn
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts Eye and Ear Infirmary
• Treatments: 4-Aminopyridine; Atenolol

Criteria

Inclusion Criteria:

• Severe vestibular migraine (VM)

Exclusion Criteria:

• Neurologic or otologic disease other than VM

• Psychiatric illness requiring medication

• Medical illness including cancer, coronary artery or cerebrovascular disease

• Known allergy to one of the test medications

• Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures

• Taking migraine prophylactic medication or vestibular suppressants.

• Pregnant or breast feeding women